Medicamen Biotech Limited (MEDICAMEQ.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-99.3%

₹1.82

vs ₹247.10 price

Levered DCF

-₹725.62

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

—

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	30.93×	88.29×	46.2×	56.17×	52.57×	55.59×	50.74×	53.7×
P/B	1.08×	2.95×	2.44×	4.24×	5.35×	5.07×	5.56×	7.45×
P/S	1.51×	3.86×	2.81×	5.83×	6.78×	5.98×	5.37×	5.27×
EV / EBITDA	13.86×	32.66×	21.21×	34.4×	31.19×	33.75×	31.95×	31.45×
Gross margin	27.3%	24.0%	47.5%	48.8%	41.6%	29.7%	27.9%	25.6%
Operating margin	6.3%	4.2%	28.8%	13.0%	16.2%	15.5%	13.4%	12.6%
Net margin	4.9%	4.4%	6.1%	10.5%	12.9%	10.8%	10.6%	9.8%
Current ratio	2.54×	2.11×	1.89×	1.98×	1.69×	1.8×	1.84×	1.98×
Debt / equity	0.17×	0.16×	0.15×	0.13×	0.18×	0.14×	0.09×	0.14×
Interest coverage	3.54×	2.15×	11.75×	5.38×	9.64×	11.57×	18.05×	11.17×
Dividend yield	0.5%	0.2%	0.3%	0.2%	0.2%	0.1%	0.2%	0.0%
Payout ratio	14.1%	17.9%	11.6%	8.5%	8.2%	5.0%	11.1%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	3.5%	3.3%	5.3%	7.7%	10.2%	9.1%	11.0%	13.9%
Return on invested capital	3.1%	1.8%	15.6%	7.1%	8.9%	8.5%	9.3%	11.6%
Return on assets	2.6%	2.4%	3.7%	5.3%	6.6%	6.3%	7.3%	8.8%
Free cash flow yield	-13.3%	-1.9%	-2.6%	-1.6%	-0.6%	-0.8%	-3.7%	-1.8%
Earnings yield	3.2%	1.1%	2.2%	1.8%	1.9%	1.8%	2.0%	1.9%
Enterprise value	₹3.1B	₹6.6B	₹5.2B	₹8.3B	₹8B	₹6.9B	₹6.8B	₹6.5B
Net debt / EBITDA	0.73×	1.47×	0.66×	0.21×	0.85×	0.73×	0.46×	0.21×
Cash conversion cycle (days)	227	212	213	156	133	46	94	96